November 12, 2014
Notes: Moller Andersen, Anders
Malmstrom, Marie Louise
Jorgensen, Lars Nannestad
Nissen, Flemming Helge
Hansen, Mark Berner
Ugeskr Laeger. 2013 May 20;175(21):1482-4.
Author Address: Kirurgisk Afdeling K, Bispebjerg Hospital, Bispebjerg Bakke 23, 2400 Kobehavn NV, Denmark. email@example.com
Reference Type: Journal Article
Record Number: 5116Author: Monami, M., Dicembrini, I. and Mannucci, E.
Title: Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
Journal: Diabetes Obes Metab
Short Title: Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
Alternate Journal: Diabetes, obesity & metabolism
ISSN: 1463-1326 (Electronic)
Accession Number: 23837679
Keywords: Diabetes Mellitus, Type 2/*drug therapy
Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/*adverse effects
Drug-Related Side Effects and Adverse Reactions
Pancreatic Neoplasms/*chemically induced
Randomized Controlled Trials as Topic
Abstract: AIM: Some observational studies reporting an increased risk of pancreatitis in association with Dipeptidyl Peptidase-4 inhibitors (DPP4i) have raised concerns on the overall safety of this class. Aim of the present meta-analysis is the systematic collection of information on pancreatitis in randomized clinical trials with DPP4i. METHODS: DATA SOURCES: an extensive Medline, Embase and Cochrane Database search for ‘vildagliptin’, ‘sitagliptin’, ‘saxagliptin’, ‘alogliptin’, ‘linagliptin’ and ‘dutogliptin’ was performed up to 1 March 2013. STUDY SELECTION: studies were included if they satisfied the following criteria: (i) randomized trials, (ii) duration >/=12 weeks, (iii) on type 2 diabetes and (iv) comparison of DPP4i with placebo or active drugs. The identification and the selection of studies, and the subsequent data extraction were performed independently by two authors. Mantel-Haenszel odds ratio with 95% Confidence Interval (MH-OR) was calculated for all the adverse events defined below. The principal outcome was the effect of DPP4i on the incidence of pancreatitis. RESULTS: A total of 134 eligible trials were identified. The overall risk of pancreatitis and pancreatic cancer was not different between DPP4i and comparators (MH-OR: 0.93[0.51-1.69]; p = 0.82). CONCLUSIONS: It should be recognized that the number of observed cases of incident pancreatitis is small and the confidence intervals of risk estimates are wide. However, the present meta-analysis do not suggest any increase in the risk of pancreatitis with DPP4i.